ARCHIVES

New Safety Concerns On ESAs Prompt FDA To Consult ODAC Again.

This article is from The Cancer Letter archive.

Vol. 34 No. 01 | January 11, 2008

Download PDF Visit The Full Archive

Related Articles

Ohio State to study center expansion.

September 26, 2003

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011

Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested

February 11, 1977

Decline In Breast Cancer May Be Related to Drop In HT

March 25, 2011

Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer

January 25, 2013

House-Senate Conferees agree On NCI Total for FY’89, Then Cut It $19 Million

August 26, 1988